Lonapegsomatropin (Skytrofa) for Growth Hormone Deficiency

Date: February 7, 2022 Issue #:  1643Summary:  Lonapegsomatropin-tcgd (Skytrofa– Ascendis), a long-acting prodrug of recombinant human growth hormone (rhGH), has been approved by the FDA for once-weekly subcutaneous (SC) treatment of growth failure due to inadequate secretion of endogenous growth hormone in children≥1 year old who weigh≥11.5 kg. It is the first once-weekly rhGH product to be approved in the US; other available rhGH formulations are administered more frequently.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Genotropin Growth hormone Humatrope lonapegsomatropin Norditropin Nutropin Omnitrope Saizen Skytrofa Zomacton Source Type: research